Mereo BioPharma, Sentynl Therapeutics Sign Licensing Deal for Alvelestat
3 Articles
3 Articles
Excesso Biopharma has developed the novel drug candidate 3,4-cPP as a platform applicable to multiple indications, including inflammatory bowel disease. Mechanisms of inflammation inhibition and vascular protection through S1PR1 protein activation were identified, and therapeutic effects were demonstrated in animal models. However, these results are at the preclinical stage and require future clinical verification.
Mereo BioPharma, Sentynl Therapeutics sign licensing deal for alvelestat
The arrangement enables Sentynl to acquire exclusive US commercial rights to alvelestat upon exercise of the option while Mereo BioPharma will retain commercial rights outside the US. Under The post Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat appeared first on Pharmaceutical Business review.
Zydus’ Sentynl enters option and licence deal for alvelestat
Sentynl Therapeutics, a US-based biopharmaceutical company and wholly owned subsidiary of Zydus Lifesciences, and Mereo BioPharma Group, a clinical-stage biopharmaceutical company focused on rare diseases, have entered into an option and licence agreement for the US commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first ora…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
